Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof
The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effective amount of the piperazine compound and a method of treating central nervous system (CNS) disorder such as psychosis in a mammal.
1. A piperazine compound represented by Formula (I) or pharmaceutically acceptable salts thereof,
wherein
n is an integer from 2 to 6,
R 1 and R 2 are the same or different and are independently selected from the group consisting of hydrogen, a hydroxyl, a halogen, nitrogen dioxide, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a straight or branched chain alkoxy group with 1 to 4 carbon atoms, and
R 3 is selected from the following groups:
wherein
m is an integer from 1 to 3,
R 4 and R 5 are the same or different and are independently selected from the group consisting of hydrogen, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a benzyl, and optionally R 4 and R 5 form a 5 to 7-membered heterocyclic ring together with nitrogen atoms to which they are attached, and
R 6 is selected from the group consisting of hydrogen, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a phenyl.
2. The piperazine compound of claim 1 , wherein the compound is an O-carbamoyl phenyl piperazine compound represented by Formula (VII) or pharmaceutically acceptable salts thereof,
wherein:
n is an integer of 2 to 6;
R 1 and R 2 are the same or different and are independently selected from the group consisting of hydrogen, a hydroxyl, a halogen, nitrogen dioxide, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a straight or branched chain alkoxy group with 1 to 4 carbon atoms;
m is an integer from 1 to 3; and
R 4 and R 5 are the same or different and are independently selected from the group consisting of hydrogen, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a benzyl, and optionally R 4 and R 5 form a 5 to 7-membered heterocyclic ring together with nitrogen atoms to which they are attached.
3. The piperazine compound of claim 1 , wherein the compound is a urea phenyl piperazine compound represented by the following Structural Formula (IX) or pharmaceutically acceptable salts thereof,
wherein:
n is an integer of 2 to 6;
R 1 and R 2 are the same or different and are independently selected from the group consisting of hydrogen, a hydroxyl, a halogen, nitrogen dioxide, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a straight or branched chain alkoxy group with 1 to 3 carbon atoms;
m is an integer of 1 to 3;
R 4 and R 5 are the same or different and are independently selected from the group consisting of hydrogen, a straight or branched chain alkyl group with 1 to 4 carbon atoms and a benzyl, and optionally R 4 and R 5 form a 5 to 7-membered heterocyclic ring together with nitrogen atoms to which they are attached; and
R 6 is selected from the group consisting of hydrogen, a straight or branched chain alkyl with 1 to 4 carbon atoms, and a phenyl.
4. The compound in accordance with claim 2 , wherein said compound is carbamic acid 4-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl ester, carbamic acid 4-{3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propoxy}-benzyl ester, carbamic acid 4-{5-[4-(2-methoxy-phenyl) -piperazin-1-yl]-ethoxy}-benzyl ester, carbamic acid 4-{5-[4-(2-methoxy-phenyl) -piperazin-1-yl]-pentyloxy}-benzyl ester, or carbamic acid 4-{4-[4-(2-fluoro-phenyl)-piperazin -1-yl]-butoxy}-benzyl ester.
5. The compound in accordance with claim 3 , wherein said compound is (4-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-urea, (3-{4-[4-(2-methoxy-phenyl)-piperazin -1-yl]-butoxy}-benzyl)-urea, 1-(4-(4-{4-[4-(2-chloro-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-1-methyl-urea, 3-(4-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-1,1-dimethyl-urea, 3-(3-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-1,1-dimethyl-urea, 1-(4-{4-[4-(2-methoxy -phenyl)-piperazin-1-yl]-butoxy}-benzyl)-3-methyl-urea, 1-(4-{4-[4-(2,3-dichloro-phenyl)-piperazin -1-yl]-butoxy}-benzyl)-1,3,3-trimethyl-urea, or 1-(4-{4-[4(2-chloro-phenyl)-piperazin-1-yl ]-butoxy}-benzyl)-1-methyl-3-phenyl-urea.
6. A pharmaceutical composition comprising an effective amount of the piperazine compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
7. The pharmaceutical composition of claim 6 , wherein the composition comprises an effective amount of an O-carbamoyl phenyl piperazine compound represented by Formula (VII) or pharmaceutically acceptable salts thereof,
wherein:
n is an integer of 2 to 6;
R 1 and R 2 are the same or different and are independently selected from the group consisting of hydrogen, a hydroxyl, a halogen, nitrogen dioxide, a straight or branched chain alkyl group of from 1 to 4 carbon atoms, and a straight or branched chain alkoxy group with 1 to 4 carbon atoms;
m is an integer of 1 to 3; and
R 4 and R 5 are the same or different and are independently selected from the group consisting of hydrogen, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a benzyl, and optionally R 4 and R 5 form a 5 to 7-membered heterocyclic ring together with nitrogen atoms to which they are attached.
8. The pharmaceutical composition of claim 7 , wherein the compound is carbamic acid 4-{4-[4(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl ester, carbamic acid 4-{3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propoxy}-benzyl ester, carbamic acid 4-{2-[4-(2-methoxy -phenyl)-piperazin-1-yl]-ethoxy}-benzyl ester, carbamic acid 4-{5-[4-(2-methoxy-phenyl) -piperazin-1-yl]-pentyloxy}-benzyl ester, or carbamic acid 4-{4-[4-(2-fluoro-phenyl)-piperazin -1-yl]-butoxy}-benzyl ester.
9. The pharmaceutical composition of claim 6 , wherein the composition comprises an effective amount of a urea phenyl piperazine compound represented by Formula (IX) or pharmaceutically acceptable salts thereof,
wherein:
n is an integer of 2 to 6;
R 1 and R 2 are the same or different and are independently selected from the group consisting of hydrogen, a hydroxyl, a halogen, nitrogen dioxide, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and a straight or branched chain alkoxy group with 1 to 4 carbon atoms;
m is an integer of 1 to 3;
R 4 and R 5 are the same or different and are independently selected from the group consisting of hydrogen, a straight or branched chain alkyl group with 1 to 4 carbon atoms, and benzyl, and optionally R 4 and R 5 form a 5 to 7-membered heterocyclic ring together with nitrogen atoms to which they are attached; and
R 6 is selected from the group consisting of hydrogen, a straight or branched chain alkyl with 1 to 4 carbon atoms, and a phenyl.
10. The pharmaceutical composition of claim 9 , wherein said compound is 4-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]butoxy}-benzyl)-urea, (3-{4-[4(2-methoxy-phenyl)-piperazin -1-yl]-butoxy}-benzyly)urea, 1-(4-{4-[4-(2-chloro-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-1-methyl-urea, 3-(4-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-1,1-dimethyl-urea, 3-(3-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-butoxy}-benzyl)-1,1-dimethyl-urea, 1-(4-{4-[4(2-methoxy -phenyl)-piperazin-1-yl]-butoxy}-benzyl)-3-methyl-urea, 1-(4-{4-[4-(2,3-dichloro-phenyl)-piperazin -1-yl]-butoxy}-benzyl)-1,3,3-trimethyl-urea, or 1-(4-{4-[4-(2-chloro-phenyl)-piperazin-1-yl ]-butoxy}-benzyl)-1-methyl-3-phenyl-urea.